Teplizumab approval for type 1 diabetes in the USA-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Teplizumab approval for type 1 diabetes in the USA

Published:2023-02 Issue:2 Volume:11 Page:78-80
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Beran David,Abidha Carol,Adler Amanda,de Beaufort Carine,Lepeska Molly,Levitt Naomi,Pfiester Elizabeth,Zafra-Tanaka Jessica H,Gale Edwin AM

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference3 articles.

1. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes;Herold;N Engl J Med,2019

2. The emotional well-being of parents with children at genetic risk for type 1 diabetes before and during participation in the POInT-study;Houben;Pediatr Diabetes,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Islet‐Resident Memory T Cells Orchestrate the Immunopathogenesis of Type 1 Diabetes through the FABP4‐CXCL10 Axis;Advanced Science;2024-06-17

2. Efficacy of teplizumab for treatment of type 1 diabetes: A meta‐analysis of randomized controlled trials;Diabetes/Metabolism Research and Reviews;2024-05

3. Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus;Clinical Immunology;2024-05

4. New advances in type 1 diabetes;BMJ;2024-01-26

5. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics;Immunology;2023-12-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP